Brian Mann

Updated at 7:20 p.m. ET

Newly public documents paint a detailed and often damning portrait of the role played by members of the Sackler family, owners of Purdue Pharma, during years when the privately owned drug company launched criminal schemes designed to "turbocharge" sales of Oxycontin and other highly addictive opioid medications.

A federal bankruptcy judge approved a controversial $8.3 billion settlement late Tuesday between Purdue Pharma and the Department of Justice.

The deal first unveiled last month stems from the company's decades-long manufacture and marketing of Oxycontin and other highly addictive opioid medications.

Under terms approved by Judge Robert Drain, Purdue Pharma will plead guilty to three felony counts of criminal wrongdoing.